MicroEye® is approved for use in the peripheral vascular system and in subcutaneous, intramuscular and adipose tissue. Most small water-soluble molecules can be monitored, and many including glucose and lactate can be monitored in real time, helping to improve clinical outcomes in a range of specialties including intensive care, cardiology, surgery, emergency medicine, paediatrics and neonatology.
Continuous and automated real-time online monitoring of blood glucose using MicroEye® may provide accurate data for improved management of some patient groups.
Although around 10 per cent of intensive care patients may be diabetic, the incidence of stress-induced hyperglycaemia has been reported to range from 30 to 100 per cent.
Effective control of blood glucose levels reduces the incidence of hyperglycaemia and hypoglycaemia, both of which may compromise patient safety.
- MicroEye® delivers real-time blood glucose data which meets ISO 15197 accuracy criteria.
- Improved patient outcomes.
- Speedier recovery and shorter hospital stays.
MicroEye® can be used to assess metabolic stress by monitoring blood lactate levels. High blood lactate (hyperlactatemia) is frequently found in critically ill patients and often used as a marker of adverse outcome.
A study* looking at all adult ICU admissions (n=13,932) in a healthcare institution over a three-year period found incidences of high blood lactate between 40 and 45 per cent. There was also a highly significant association between hyperlactatemia (blood lactate > 2 mmol/L) and mortality rates of 27 per cent.
Other studies show that mortality rates of nearly 70 per cent are independently associated with blood lactate levels of at least 3.5 mmol/L.
- Gives a reliable measure of cellular hypoxia.
- Helps assess the effectiveness of therapeutic interventions.
- Applications in cardiology, obstetrics and gynaecology, as well as intensive care.
To find out more about the benefits of using MicroEye® in a critical care environment, please email firstname.lastname@example.org.